Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares Semiconductor ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while iShares Semiconductor ETF trades at $546.66. The key difference: iShares Semiconductor ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SOXX | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $655.01 |
52-Week Low | $0.48 | $241.68 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
SOXX trades at $552.56, up 4.24% with a bullish technical signal from moving averages. The semiconductor ETF faces mixed sentiment as recent news highlights sector rotation away from chips toward software, though major cloud companies' strong earnings support AI infrastructure demand. Technical indicators show neutral oscillators with key resistance at $548.
Outlook remains cautiously optimistic given AI-driven semiconductor demand, but risks include tariff impacts, concentration in 30 stocks, and potential overvaluation after 2026 gains. Institutional buying (Bank of America increased holdings 20.9% in Q1 2026) signals confidence, yet investor caution is warranted amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
